Cargando…
Immune status for monitoring and treatment of bladder cancer
The high recurrence rate of non-muscle invasive bladder cancer (BC) and poor prognosis of advanced BC are therapeutic challenges that need to be solved. Bacillus Calmette-Guerin (BCG) perfusion was the pioneer immunotherapy for early BC, and the discovery of immune checkpoint inhibitors has created...
Autores principales: | Pan, Shen, Li, Shijie, Zhan, Yunhong, Chen, Xiaonan, Sun, Ming, Liu, Xuefeng, Wu, Bin, Li, Zhenhua, Liu, Bitian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492838/ https://www.ncbi.nlm.nih.gov/pubmed/36159866 http://dx.doi.org/10.3389/fimmu.2022.963877 |
Ejemplares similares
-
Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint Inhibitors
por: Pan, Shen, et al.
Publicado: (2019) -
Identification of Biomarkers for Controlling Cancer Stem Cell Characteristics in Bladder Cancer by Network Analysis of Transcriptome Data Stemness Indices
por: Pan, Shen, et al.
Publicado: (2019) -
Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer
por: Li, Shijie, et al.
Publicado: (2023) -
Identification of a Gene Signature for Renal Cell Carcinoma–Associated Fibroblasts Mediating Cancer Progression and Affecting Prognosis
por: Liu, Bitian, et al.
Publicado: (2021) -
Laparoscopic ultrasonography: The wave of the future in renal cell carcinoma?
por: Liu, Bitian, et al.
Publicado: (2018)